Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ropivacaine hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - surgical anaesthesia (adults and children over 12 years of age). - epidural block for surgery including caesarean section. - intrathecal anaesthesia. - field block (minor nerve block and infiltration). - major nerve block. analgesia (adults and children over 12 years of age). - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). - continuous peripheral nerve block infusion or intermittent injections for post operative pain management. analgesia (children aged 0 - 12 years). - caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years . - continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years. - peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections support the use for up to 48 hours only).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ropivacaine hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - surgical anaesthesia (adults and children over 12 years of age). - epidural block for surgery including caesarean section. - intrathecal anaesthesia. - field block (minor nerve block and infiltration). - major nerve block. analgesia (adults and children over 12 years of age). - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). - continuous peripheral nerve block infusion or intermittent injections for post operative pain management. analgesia (children aged 0 - 12 years). - caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years . - continuous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years. - peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections support the use for up to 48 hours only).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine sulfate pentahydrate, quantity: 30 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride - indications as at 7 july 2020: dbl morphine sulfate injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. dbl morphine sulfate injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine sulfate pentahydrate, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - indications as at 7 july 2020: dbl morphine sulfate injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. dbl morphine sulfate injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 2700 pfu/ml - injection, powder for - excipient ingredients: monobasic potassium phosphate; potassium chloride; hydrolysed gelatin; sodium chloride; dibasic sodium phosphate; urea; sucrose; monosodium glutamate monohydrate - varivax refrigerated is indicated for vaccination against varicella in healthy individuals 12 months of age and older.,see the australian immunisation handbook for vaccination recommendations and schedule.,groups who would particularly benefit from vaccination include:,? non-immune adults, especially those in at-risk occupations such as health-care workers, teachers and workers in children?s day-care centres.,? non-immune parents of young children.,? non-immune household contacts, both adults and children, of immunocompromised patients with no history of disease.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine sulfate pentahydrate, quantity: 15 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - indications as at 7 july 2020: dbl morphine sulfate injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. dbl morphine sulfate injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - indications as at 7 july 2020: dbl morphine sulfate injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. dbl morphine sulfate injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 500 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - antineoplastic chemotherapy - treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic and meningeal leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemia. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methotrexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. high dose therapy - the use of very high doses is made possible by vials for injection containing 500 mg and 1000 mg (see precautions). diseases treated with these doses administered in the form of single-drug or combination therapy, include osteogenic sarcoma, acute leukaemia, bronchogenic carcinoma and epidermoid carcinoma of the head and n

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - antineoplastic chemotherapy: methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. methotrexate may be used in combination with other chemotherapeutic agents for the palliative treatment of acute leukaemias, particularly acute lymphoblastic leukaemia. it may also be used in the treatment of burkitt's lymphoma, advanced stages (iii and iv, peters' staging system) of lymphosarcoma, especially in children, and in advanced cases of mycosis fungoides. high dose therapy: in high-dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy (see warning box): methotrexate may be of value in the symptomatic control o

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - glatiramer acetate, quantity: 40 mg - injection, solution - excipient ingredients: mannitol; water for injections - copaxone is indicated for the: 1- reduction of the frequency of relapses in patients with relapsing remitting multiple sclerosis. 2-treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent mri lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.